Arbutus Biopharma Corp
Moat Score — Arbutus Biopharma Corporation
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Arbutus's foundational lipid nanoparticle (LNP) delivery patents were emphatically validated by the $2.25 billion Moderna settlement and a favorable claim-construction ruling in the ongoing Pfizer/BioNTech case, making this one of the strongest demonstrated intangible-asset moats of any small-cap biotech — a patent estate that major mRNA-vaccine and RNAi-drug makers have been found to depend on. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Arbutus has no manufacturing or commercial operations and therefore no cost advantage; its value is derived entirely from intellectual property licensing/litigation and early-stage clinical development, not production economics. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | As the holder of foundational LNP delivery patents that major pharmaceutical companies' marketed products depend on, Arbutus (via Genevant) has real negotiating leverage in royalty and settlement discussions, evidenced by the scale of the Moderna settlement, though this leverage applies only to a narrow set of licensees/infringers rather than a broad pricing lever. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in either the licensing/IP business or the hepatitis B therapeutic pipeline — the value of Arbutus's patents or its drug candidate to one licensee or patient does not depend on how many others use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Companies that have already built and received regulatory approval for commercial products (such as Moderna's mRNA vaccines) using LNP delivery technology covered by Arbutus's patents face very high practical switching costs to a different, non-infringing delivery technology, which is precisely why litigation and settlement, rather than design-around, has been the outcome. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Arbutus's patent estate creates a real barrier for new entrants seeking to develop competing LNP delivery technology without infringement risk, but this is better captured under intangible assets than efficient scale, and the company itself has no operating scale of its own. |